GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Fisher & Paykel Healthcare Corp Ltd (NZSE:FPH) » Definitions » Altman Z-Score

Fisher & Paykel Healthcare (NZSE:FPH) Altman Z-Score : 24.29 (As of Apr. 30, 2024)


View and export this data going back to 1979. Start your Free Trial

What is Fisher & Paykel Healthcare Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 23.46 is strong.

Fisher & Paykel Healthcare has a Altman Z-Score of 24.29, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Fisher & Paykel Healthcare's Altman Z-Score or its related term are showing as below:

NZSE:FPH' s Altman Z-Score Range Over the Past 10 Years
Min: 8.63   Med: 20.46   Max: 25.26
Current: 23.46

During the past 13 years, Fisher & Paykel Healthcare's highest Altman Z-Score was 25.26. The lowest was 8.63. And the median was 20.46.


Fisher & Paykel Healthcare Altman Z-Score Historical Data

The historical data trend for Fisher & Paykel Healthcare's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fisher & Paykel Healthcare Altman Z-Score Chart

Fisher & Paykel Healthcare Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.02 25.26 23.10 22.44 22.78

Fisher & Paykel Healthcare Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 22.44 - 22.78 -

Competitive Comparison of Fisher & Paykel Healthcare's Altman Z-Score

For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fisher & Paykel Healthcare's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Fisher & Paykel Healthcare's Altman Z-Score falls into.



Fisher & Paykel Healthcare Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Fisher & Paykel Healthcare's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.2197+1.4*0.5446+3.3*0.1518+0.6*36.7422+1.0*0.7206
=24.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2023:
Total Assets was NZ$2,205 Mil.
Total Current Assets was NZ$774 Mil.
Total Current Liabilities was NZ$290 Mil.
Retained Earnings was NZ$1,201 Mil.
Pre-Tax Income was NZ$328 Mil.
Interest Expense was NZ$-7 Mil.
Revenue was NZ$1,589 Mil.
Market Cap (Today) was NZ$16,574 Mil.
Total Liabilities was NZ$451 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(774.2 - 289.8)/2204.5
=0.2197

X2=Retained Earnings/Total Assets
=1200.5/2204.5
=0.5446

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(328 - -6.7)/2204.5
=0.1518

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=16574.390/451.1
=36.7422

X5=Revenue/Total Assets
=1588.6/2204.5
=0.7206

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Fisher & Paykel Healthcare has a Altman Z-Score of 24.29 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Fisher & Paykel Healthcare  (NZSE:FPH) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Fisher & Paykel Healthcare Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Fisher & Paykel Healthcare's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fisher & Paykel Healthcare (NZSE:FPH) Business Description

Traded in Other Exchanges
Address
15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnoea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the U.S., 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.

Fisher & Paykel Healthcare (NZSE:FPH) Headlines